Eli Lilly to invest over $1 billion in India to expand manufacturing capacity

Eli Lilly is committing over $1 billion to expand manufacturing and supply capabilities in India through local partnerships, aiming to bolster global availability of key drugs for obesity, diabetes, and other conditions. This strategic investment, which includes a new Hyderabad facility to oversee contract manufacturing, leverages India's skilled workforce and positions Lilly for market growth despite looming generic competition. The move reflects a broader global expansion strategy, complementing significant U.S. manufacturing investments amidst evolving international trade dynamics.

Analysis

Oct 6 (Reuters) - Eli Lilly (LLY.N) will invest more than $1 billion in India in the coming years to boost manufacturing and supply through local drugmakers, the company said on Monday, as it seeks to tap into skilled workforce to bolster its global manufacturing expansion. The collaborations aim to increase the availability of Lilly's key drugs, including those for obesity, diabetes, Alzheimer's, cancer and autoimmune conditions, the company said. Keep up with the latest medical breakthroughs and healthcare trends with the Reuters Health Rounds newsletter. Sign up here. Advertisement · Scroll to continue "We are making significant investments to increase manufacturing and medicine supply capacity around the world," Patrik Jonsson, president of Lilly International, said, adding, India is a hub for capability building within its global network. The company, which launched its blockbuster weight-loss drug Mounjaro in India this year, currently does not operate its own manufacturing facility in the country, which hosts several firms that develop and manufacture complex drugs, vials, injectables for larger pharmaceuticals on a contract basis. "Lilly is actively engaging with contract manufacturers in India," the company told Reuters, but did not divulge any further details. Advertisement · Scroll to continue Lilly's investment plans in India come at a time when global drugmakers are rushing to bolster U.S. manufacturing capacity after the Trump administration imposed a 100% tariff on imported branded and patented drugs from October 1. Last month, Lilly announced a $5 billion investment in a new facility in Virginia, part of a $27 billion expansion plan to build four new U.S. plants over the next five years. Meanwhile, the India launch of Mounjaro, alongside Danish drugmaker Novo Nordisk's (NOVOb.CO) Wegovy, has increased patient awareness of obesity treatments in a country projected to have the world's second-largest obese population by 2050. Sales of both drugs doubled within months of their launch. Lilly is also preparing for increased competition from India's generic drugmakers, who are racing to launch cheaper versions of Wegovy once its main chemical ingredient, semaglutide, goes off patent next year. Separately, Lilly is setting up a manufacturing and quality facility in the southern Indian city of Hyderabad to expand its presence beyond the city's global capability center. The new hub will oversee the firm's contract manufacturing network across India and provide technical capabilities. Recruitment for the new site "will begin immediately", Lilly said, with plans to hire engineers, chemists, analytical scientists, quality control and assurance experts and managers. Reporting by Rishika Sadam; Editing by Sumana Nandy Our Standards: The Thomson Reuters Trust Principles. Eli Lilly's commitment to invest over $1 billion in India represents a strategic diversification of its global manufacturing base, aimed at leveraging the country's skilled workforce and established contract manufacturing ecosystem. This move is designed to scale up the supply of its high-demand drug portfolio, including the blockbuster obesity treatment Mounjaro, in a market where initial sales have already doubled. The establishment of a new quality and manufacturing hub in Hyderabad will provide crucial oversight for this outsourced production. This India-focused expansion complements a massive $27 billion, multi-year investment in new U.S. facilities, which is partly a response to geopolitical factors like the 100% tariff on certain imported drugs. While this dual-pronged strategy positions Lilly to capitalize on significant growth in India, it also acknowledges impending competitive pressures. The article highlights that Indian generic drugmakers are preparing to launch cheaper versions of competitor Novo Nordisk's Wegovy upon its patent expiry next year, signaling a future landscape of increased price competition in the lucrative GLP-1 market.

Key Decisions for Investors

• Lilly's simultaneous manufacturing expansion in both the U.S. and India demonstrates a robust strategy to de-risk its supply chain and mitigate geopolitical trade issues, strengthening the long-term bullish case for the company's operational stability.
• Investors should monitor the entry of generic versions of Novo Nordisk's semaglutide in India next year as a critical test for pricing power across the entire GLP-1 drug class, which could impact long-term margins for both Lilly and its competitors.
• The rapid uptake of Mounjaro in India confirms strong market demand; execution risk now shifts to Lilly's ability to effectively scale production through its new contract manufacturing partners to fully capture this growth opportunity.
• Given the high positive sentiment for Lilly versus the negative sentiment for Novo Nordisk, the market appears to favor Lilly's proactive investment and view the looming patent cliff for Wegovy's ingredient as a significant competitive headwind for its Danish rival in key emerging markets.